Comparative Pharmacology
Head-to-head clinical analysis: CARVEDILOL versus XYLOCAINE W EPINEPHRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARVEDILOL versus XYLOCAINE W EPINEPHRINE.
CARVEDILOL vs XYLOCAINE W/ EPINEPHRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carvedilol is a nonselective beta-adrenergic receptor antagonist (beta-1, beta-2) and alpha-1 adrenergic receptor antagonist. It causes vasodilation and reduces heart rate, myocardial contractility, and blood pressure. It also has antioxidant and anti-proliferative effects.
Lidocaine blocks voltage-gated sodium channels, inhibiting neuronal depolarization and conduction. Epinephrine causes vasoconstriction via alpha-1 adrenergic receptor agonism, reducing systemic absorption and prolonging local anesthetic action.
Heart failure: Initial 3.125 mg orally twice daily, titrate every 2 weeks to 6.25 mg, 12.5 mg, then 25 mg twice daily as tolerated. Target dose: 25 mg twice daily (≤85 kg) or 50 mg twice daily (>85 kg). Hypertension: Initial 6.25 mg orally twice daily, titrate every 1-2 weeks to 12.5 mg, then 25 mg twice daily. Maximum: 50 mg twice daily.
Adults: 1-5 mL of 1% or 2% solution (maximum 7 mg/kg lidocaine without epinephrine; 7 mg/kg with epinephrine; not to exceed 500 mg total) by infiltration or nerve block, not to be repeated within 2 hours.
None Documented
None Documented
Clinical Note
moderateCarvedilol + Digitoxin
"Carvedilol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateCarvedilol + Deslanoside
"Carvedilol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateCarvedilol + Acetyldigitoxin
"Carvedilol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateCarvedilol + Ouabain
"Carvedilol may increase the bradycardic activities of Ouabain."
Terminal elimination half-life is 7-10 hours. Steady-state concentrations are achieved within 2-3 days. Clinical context: Twice-daily dosing provides consistent beta-blockade and vasodilation.
Lidocaine terminal half-life: ~1.5-2 hours (initial); ~2-4 hours (terminal) after IV. Prolonged in hepatic dysfunction (up to 5-7 hours) and congestive heart failure (up to 10 hours).
Primarily hepatic metabolism, with less than 2% excreted unchanged in urine. Metabolites are excreted in bile and feces; renal clearance of metabolites accounts for ~16% of total clearance. Fecal excretion of metabolites is ~60%.
Renal: lidocaine and metabolites (primarily 4-hydroxyxylidine and glycinexylidide) ~90% as metabolites, <10% unchanged. Biliary/fecal: minor (approximately 3-5%).
Category C
Category A/B
Alpha/Beta-Blocker
Alpha/Beta Agonist